1:- BACKGROUND OF SP-D found in lung surfactant, is an innate immunity molecule with immune-modulatory properties and is important in clearing airways viruses. Low or Absent level of SP-D in lung lavage has been observed in patients with COPD, Asthma with excessive exacerbations and in the premature babies and has been linked with level of inflamationin the lung. Human Rhinovirus and Respiratory Syncytial Virus has been linked with exacerbation in adults with COPD and Asthma and is also a problem in preterm babies. A recombinant fragment of human SP-D has been developed and shown to have the same anti-inflammatory properties as native full length SP-D and is currently in the process of being tested in ”first in man” safety phase I trial in spring in 2021. 2:-METHODS:– The aim of the project is to investigate the interaction of rfhSP-D with human rhinovirus and Respiratory syncytial virus in detail and evaluate whether in time line of viral infection, SP-D therapy might have the best impact. Project used various methods including western blotting, CO-immunoprecipitation, ELISA, Surfactant Resonance Plasmon with recombinant viral surface proteins and in vitro and in vivo infection models where the outcome include viral titres and level of cytokines. CONCLUSION:- THIS INFORMATION COULD BE USEFUL IN EVALUATION IF rfhSP-D has the potential to be developed as an antiviral agent against Human rhinovirus and Respiratory syncytial virus.Show more
